Intensive management of obesity in people with severe chronic kidney disease: A review.
VLEDs
bariatric surgery
end-stage kidney disease
obesity
obesity pharmacotherapy
weight loss
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
06
04
2021
received:
07
02
2021
accepted:
22
04
2021
pubmed:
28
4
2021
medline:
7
8
2021
entrez:
27
4
2021
Statut:
ppublish
Résumé
Obesity is highly prevalent worldwide, including among people with chronic kidney disease (CKD). The presence of severe and/or end-stage kidney disease complicates the treatment of obesity for several reasons, including restrictions on protein and fluid intake and renal excretion of several medications indicated for the treatment of obesity. The aim of this review is to assess the safety of intensive obesity treatments, such as very-low-energy diets (VLEDs), obesity pharmacotherapy and/or bariatric surgery, in people with end-stage kidney disease. A literature search was conducted to identify studies reporting safety outcomes for VLEDs, liraglutide, phentermine, phentermine-topiramate, naltrexone-bupropion and bariatric surgery in people with an estimated glomerular filtration rate of less than 30 mL/min/1.73m
Substances chimiques
Phentermine
C045TQL4WP
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1733-1745Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395:709-733.
GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1923.
World Health Organisation: Obesity and overweight. 2020. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed November 30, 2020.
Yun H-R, Kim H, Park JT, et al. Obesity, metabolic abnormality, and progression of CKD. Am J Kidney Dis. 2018;72:400-410.
Pinto-Sietsma S-J, Navis G, Janssen WMT, de Zeeuw D, Gans ROB, de Jong PE. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis. 2003;41:733-741.
Docherty NG, le Roux CW. Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nat Rev Nephrol. 2020;16:709-720.
Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1565-1574.
Jensen M, Ryan D, Apovian C, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. Circulation. 2014;129:S139-S140.
Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med. 2017;377:1765-1776.
Food and Drug Administration: Contrave (naltrexone HCl and bupropion HCl). 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf. Accessed December 2, 2020.
Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine. 2014;46:406-419.
Chintam K, Chang AR. Strategies to treat obesity in patients with CKD. Am J Kidney Dis. 2020;77(3):427-439.
Zhang L, Wang Y, Xiong L, Luo Y, Huang Z, Yi B. Exercise therapy improves eGFR, and reduces blood pressure and BMI in non-dialysis CKD patients: evidence from a meta-analysis. BMC Nephrol. 2019;20:398.
Hossain M, Woywodt A, Augustine T, Sharma V. Obesity and listing for renal transplantation: weighing the evidence for a growing problem. Clin Kidney J. 2017;10:703-708.
Friedman AN, Chambers M, Kamendulis LM, Temmerman J. Short-term changes after a weight reduction intervention in advanced diabetic nephropathy. Clin J Am Soc Nephrol. 2013;8:1892-1898.
Idorn T, Knop FK, Jørgensen MB, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. Diabetes Care. 2016;39:206-213.
Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839-848.
MacLaughlin HL, Cook SA, Kariyawasam D, Roseke M, van Niekerk M, Macdougall IC. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. Am J Kidney Dis. 2010;55:69-76.
Takata MC, Campos GM, Ciovica R, et al. Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation. Surg Obes Relat Dis. 2008;4:159-164.
Jamal MH, Corcelles R, Daigle CR, et al. Safety and effectiveness of bariatric surgery in dialysis patients and kidney transplantation candidates. Surg Obes Relat Dis. 2015;11:419-423.
Proczko M, Pouwels S, Kaska L, Stepaniak PS. Applying enhanced recovery after bariatric surgery (ERABS) protocol for morbidly obese patients with end-stage renal failure. Obes Surg. 2019;29:1142-1147.
Modanlou KA, Muthyala U, Xiao H, et al. Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation. 2009;87:1167-1173.
Sheetz KH, Woodside KJ, Shahinian VB, Dimick JB, Montgomery JR, Waits SA. Trends in bariatric surgery procedures among patients with ESKD in the United States. Clin J Am Soc Nephrol. 2019;14:1193-1199.
Yemini R, Nesher E, Carmeli I, et al. Bariatric surgery is efficacious and improves access to transplantation for morbidly obese renal transplant candidates. Obes Surg. 2019;29:2373-2380.
Alexander JW, Goodman H. Gastric bypass in chronic renal failure and renal transplant. Nutr Clin Pract. 2007;22:16-21.
MacLaughlin HL, Hall WL, Patel AG, Macdougall IC. Laparoscopic sleeve gastrectomy is a novel and effective treatment for obesity in patients with chronic kidney disease. Obes Surg. 2012;22:119-123.
Valle GA, Kissane BE, de la Cruz-Muñoz N. Successful laparoscopic bariatric surgery in peritoneal dialysis patients without interruption of their CKD6 treatment modality. Adv Perit Dial. 2012;28:134-139.
Mozer AB, Pender JR, Chapman WH, Sippey ME, Pories WJ, Spaniolas K. Bariatric surgery in patients with dialysis-dependent renal failure. Obes Surg. 2015;25:2088-2092.
Saleh F, Kim SJ, Okrainec A, Jackson TD. Bariatric surgery in patients with reduced kidney function: an analysis of short-term outcomes. Surg Obes Relat Dis. 2015;11:828-835.
Andalib A, Aminian A, Khorgami Z, Navaneethan SD, Schauer PR, Brethauer SA. Safety analysis of primary bariatric surgery in patients on chronic dialysis. Surg Endosc. 2016;30:2583-2591.
Kienzl-Wagner K, Weissenbacher A, Gehwolf P, Wykypiel H, Öfner D, Schneeberger S. Laparoscopic sleeve gastrectomy: gateway to kidney transplantation. Surg Obes Relat Dis. 2017;13:909-915.
Kim Y, Shi J, Freeman CM, et al. Addressing the challenges of sleeve gastrectomy in end-stage renal disease: analysis of 100 consecutive renal failure patients. Surgery. 2017;162:358-365.
Al-Bahri S, Fakhry TK, Gonzalvo JP, Murr MM. Bariatric surgery as a bridge to renal transplantation in patients with end-stage renal disease. Obes Surg. 2017;27:2951-2955.
Kim Y, Jung AD, Dhar VK, et al. Laparoscopic sleeve gastrectomy improves renal transplant candidacy and posttransplant outcomes in morbidly obese patients. Am J Transplant. 2018;18:410-416.
Cohen JB, Tewksbury CM, Torres Landa S, Williams NN, Dumon KR. National postoperative bariatric surgery outcomes in patients with chronic kidney disease and end-stage kidney disease. Obes Surg. 2019;29:975-982.
Hansel B, Arapis K, Kadouch D, et al. Severe chronic kidney disease is associated with a lower efficiency of bariatric surgery. Obes Surg. 2019;29:1514-1520.
Mazzei M, Zhao H, Edwards MA. The impact of chronic kidney disease on bariatric perioperative outcome: a MBSAQIP matched analysis. Surg Obes Relat Dis. 2019;15:2075-2086.
Bouchard P, Tchervenkov J, Demyttenaere S, Andalib A. Safety and efficacy of the sleeve gastrectomy as a strategy towards kidney transplantation. Surg Endosc. 2020;34:2657-2664.
Kassam AF, Mirza A, Kim Y, et al. Long-term outcomes in patients with obesity and renal disease after sleeve gastrectomy. Am J Transplant. 2020;20:422-429.
Gaillard M, Tranchart H, Beaudreuil S, et al. Laparoscopic sleeve gastrectomy for morbid obesity in renal transplantation candidates: a matched case-control study. Transpl Int. 2020;33(9):1061-1070.
Sheetz KH, Gerhardinger L, Dimick JB, Waits SA. Bariatric surgery and long-term survival in patients with obesity and end-stage kidney disease. JAMA Surg. 2020;155:581-588.
Dobrzycka M, Proczko-Stepaniak M, Kaska Ł, Wilczyński M, Dębska-Ślizień A, Kobiela J. Weight loss after bariatric surgery in morbidly obese end-stage kidney disease patients as preparation for kidney transplantation. Matched pair analysis in a high-volume bariatric and transplant center. Obes Surg. 2020;30:2708-2714.
Purcell K, Sumithran P, Prendergast LA, Bouniu CJ, Delbridge E, Proietto J. The effect of rate of weight loss on long-term weight management: a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2:954-962.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161.
Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606-1616.
Mann JFE, Fonseca VA, Poulter NR, et al. Safety of Liraglutide in type 2 diabetes and chronic kidney disease. Clin J Am Soc Nephrol. 2020;15:465-473.
Mann JF, Fonseca V, Mosenzon O, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease: results from the LEADER trial. Circulation. 2018;138:2908-2918.
Osonoi T, Saito M, Osonoi Y, Douguchi S, Ofuchi K, Katoh M. Liraglutide improves estimated glomerular filtration rate slopes in patients with chronic kidney disease and type 2 diabetes: a 7-year retrospective analysis. Diabetes Technol Ther. 2020;22(11):828-834.
Food and Drug Administration: Byetta (Exenatide). 2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf. Accessed December 2, 2020.
Food and Drug Administration: BYDUREON® (Exenatide Extended-Release). 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdf. Accessed December 2, 2020.
Food and Drug Administration: Adlyxin (Lixisenatide). 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471orig1s000lbl.pdf. Accessed December 2, 2020.
Food and Drug Administration: Tanzeum (Albiglutide). 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf. Accessed December 2, 2020.
Food and Drug Administration: Trulicity (Dulaglutide). 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125469s007s008lbl.pdf. Accessed December 2, 2020.
Food and Drug Administration: Victoza (Liraglutide). 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf. Accessed December 2, 2020.
Food and Drug Administration: Ozempic (Semaglutide). 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Accessed December 2, 2020.
Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6:605-617.
Granhall C, Søndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57:1571-1580.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
Mann JF, Hansen T, Idorn T, et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8:880-893.
Cohen RV, Pereira TV, Aboud CM, et al. Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial. JAMA Surg. 2020;155:e200420.